2021
575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT). Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.Peer-Reviewed Original Research
2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weeklyClinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplantPredictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant
Isufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant. Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.Peer-Reviewed Original ResearchRelapse-free survivalPET-CT scanTime of SCTTime of alloSCTPET-CTT-NHLBM biopsyAllo-SCTCT scanPositive PET/CT scanPredictive valueLong-term relapse-free survivalPositive PET-CT scanAllogeneic stem cell transplantPeripheral blood flow cytometryPET/CT scansIntermediate-high riskBlood flow cytometryAggressive clinical courseStem cell transplantT-cell lymphomaMajority of ptsPositive PET-CTAuto-SCTMedian followCardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat
Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 244-251.e4. PMID: 32067953, DOI: 10.1016/j.clml.2019.12.027.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantCardiac eventsStem cell transplantCell transplantAtrial arrhythmiasAcute heart failureInstances of bradycardiaNew-onset hypertensionAcute coronary syndromeCoronary artery diseaseRisk of deathMultivariable regression analysisCoronary syndromeOnset hypertensionHSCT populationArtery diseaseHeart failureHSCT outcomesPericardial effusionAtrial dilationVentricular arrhythmiasSingle institutionSubgroup analysisBody of evidenceMedical history
2015
The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.Peer-Reviewed Original ResearchConceptsGastrointestinal acute GVHDAcute GVHDGrade IIIAllogeneic stem cell transplantCombination of basiliximabSevere GI GvHDSevere grade IIISteroid-refractory diseaseLong-term survivorsStem cell transplantOverall response rateCurrent retrospective studyChronic GVHDGI GVHDSalvage therapySteroid therapyPrimary diseaseCell transplantMedian timeSignificant morbidityPoor outcomeRetrospective studyGVHDMost deathsNew agents
2013
A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients
Fraser J, Lansigan F, Seropian S, Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients. Blood 2013, 122: 4356. DOI: 10.1182/blood.v122.21.4356.4356.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory T-cell lymphomaStarting doseStage IIBSkin toxicityPilot studyClinical activityRelapsed T-cell lymphomaAllogeneic stem cell transplantAngioimmunoblastic T-cell lymphomaT-cell lymphoma patientsPlatelet-derived growth factor receptor alphaProgression-free survivalStem cell transplantDuration of responseGrowth factor receptor alphaOff-label useT-cell NHLNumber of therapiesMulti-kinase inhibitorAdvisory CommitteeClinical CRStable disease
2010
A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.
Lansigan F, Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood 2010, 116: 2816. DOI: 10.1182/blood.v116.21.2816.2816.Peer-Reviewed Original ResearchDose level 3Stem cell transplantStable diseaseHL patientsHodgkin's lymphomaPartial responseRefractory lymphomaCell transplantCardiac toxicityDisease progressionLiposomal doxorubicinLymphoplasmacytic lymphomaGrade 3Prior treatmentAST/ALT elevationAutologous stem cell transplantMedian age 69 yearsAllogeneic stem cell transplantPeripheral T-cell lymphomaTherapy warrants further investigationDisease controlLarge B-cell lymphomaDose level 1Dose level 2Doses of vorinostat